Cocrystal Pharma Inc
8CC
Company Profile
Business description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Contact
19805 North Creek Parkway
BothellWA98011
USAT: +1 877 262-7123
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,747.20 | 68.60 | 0.79% |
| CAC 40 | 7,743.92 | 17.72 | 0.23% |
| DAX 40 | 22,636.91 | 16.95 | -0.07% |
| Dow JONES (US) | 46,124.06 | 84.41 | -0.18% |
| FTSE 100 | 9,965.16 | 71.01 | 0.72% |
| HKSE | 25,137.92 | 74.21 | 0.30% |
| NASDAQ | 21,761.89 | 184.87 | -0.84% |
| Nikkei 225 | 53,616.45 | 1,364.17 | 2.61% |
| NZX 50 Index | 12,919.92 | 218.17 | 1.72% |
| S&P 500 | 6,556.37 | 24.63 | -0.37% |
| S&P/ASX 200 | 8,539.10 | 50.50 | 0.59% |
| SSE Composite Index | 3,918.41 | 37.13 | 0.96% |